COLL
Income statement / Annual
Last year (2023), Collegium Pharmaceutical, Inc.'s total revenue was $566.77 M,
an increase of 22.17% from the previous year.
In 2023, Collegium Pharmaceutical, Inc.'s net income was $48.16 M.
See Collegium Pharmaceutical, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$566.77 M
|
$463.93 M
|
$276.87 M
|
$310.02 M
|
$296.70 M
|
$280.41 M
|
$28.48 M
|
$1.71 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$240.60 M |
$254.45 M |
$126.25 M |
$130.18 M |
$193.66 M |
$165.68 M |
$2.60 M |
$213,000.00 |
$171,000.00 |
$0.00 |
| Gross Profit |
$326.17 M |
$209.49 M |
$150.62 M |
$179.84 M |
$103.04 M |
$114.74 M |
$25.88 M |
$1.50 M |
-$171,000.00 |
$0.00 |
| Gross Profit Ratio |
0.58 |
0.45 |
0.54 |
0.58 |
0.35 |
0.41 |
0.91 |
0.88 |
0 |
0 |
| Research and Development
Expenses |
$0.00
|
$3.98 M
|
$9.45 M
|
$9.77 M
|
$10.34 M
|
$8.66 M
|
$8.57 M
|
$14.95 M
|
$7.98 M
|
$14.96 M
|
| General & Administrative
Expenses |
$151.80 M
|
$160.44 M
|
$114.77 M
|
$108.46 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$18.93 M
|
$2.71 M
|
| Selling & Marketing
Expenses |
$7.41 M
|
$11.74 M
|
$4.19 M
|
$5.37 M
|
$116.45 M
|
$126.76 M
|
$92.76 M
|
$80.63 M
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$159.21 M
|
$172.19 M
|
$118.96 M
|
$113.83 M
|
$116.45 M
|
$126.76 M
|
$92.76 M
|
$80.63 M
|
$18.93 M
|
$2.71 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$94,000.00 |
-$348,000.00 |
$0.00 |
| Operating Expenses |
$159.21 M |
$176.17 M |
$128.41 M |
$123.60 M |
$126.79 M |
$135.42 M |
$101.33 M |
$95.58 M |
$26.91 M |
$17.67 M |
| Cost And Expenses |
$399.81 M |
$430.61 M |
$254.66 M |
$253.78 M |
$320.45 M |
$301.10 M |
$103.92 M |
$95.79 M |
$26.91 M |
$17.67 M |
| Interest Income |
$15.62 M |
$1.05 M |
$12,000.00 |
$232,000.00 |
$1.94 M |
$1.69 M |
$582,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$83.34 M |
$63.21 M |
$21.01 M |
$28.88 M |
$909,000.00 |
$20.13 M |
$582,000.00 |
$94,000.00 |
$439,000.00 |
$252,000.00 |
| Depreciation &
Amortization |
$149.26 M
|
$134.39 M
|
$68.94 M
|
$61.61 M
|
$15.80 M
|
$110.91 M
|
$594,000.00
|
$655,000.00
|
$171,000.00
|
$187,000.00
|
| EBITDA |
$308.33 M
|
$168.76 M
|
$86.58 M
|
$118.07 M
|
-$6.02 M
|
$91.91 M
|
-$74.27 M
|
-$93.43 M
|
-$26.65 M
|
-$17.48 M
|
| EBITDA Ratio |
0.54 |
0.07 |
0.08 |
0.18 |
-0.07 |
-0.07 |
-2.63 |
-54.99 |
0 |
0 |
| Operating Income Ratio
|
0.29
|
-0.23
|
-0.17
|
-0.02
|
-0.08
|
-0.07
|
-2.65
|
-54.99
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$91.23 M
|
-$62.17 M
|
-$21.00 M
|
-$28.65 M
|
$1.03 M
|
-$18.44 M
|
$582,000.00
|
-$94,000.00
|
-$348,000.00
|
-$252,000.00
|
| Income Before Tax |
$75.73 M |
-$28.85 M |
-$3.37 M |
$27.58 M |
-$22.72 M |
-$39.13 M |
-$74.87 M |
-$94.18 M |
-$27.26 M |
-$17.92 M |
| Income Before Tax Ratio
|
0.13
|
-0.06
|
-0.01
|
0.09
|
-0.08
|
-0.14
|
-2.63
|
-55.04
|
0
|
0
|
| Income Tax Expense |
$27.58 M |
-$3.85 M |
-$74.89 M |
$830,000.00 |
-$14.57 M |
-$110.91 M |
-$1.16 M |
$94,000.00 |
-$91,000.00 |
$252,000.00 |
| Net Income |
$48.16 M |
-$25.00 M |
$71.52 M |
$26.75 M |
-$8.15 M |
-$39.13 M |
-$74.87 M |
-$94.18 M |
-$27.26 M |
-$17.92 M |
| Net Income Ratio |
0.08 |
-0.05 |
0.26 |
0.09 |
-0.03 |
-0.14 |
-2.63 |
-55.04 |
0 |
0 |
| EPS |
1.6 |
-0.74 |
2.05 |
0.78 |
-0.24 |
-1.19 |
-2.47 |
-3.88 |
-2.01 |
-2.4 |
| EPS Diluted |
1.29 |
-0.74 |
1.86 |
0.76 |
-0.24 |
-1.19 |
-2.47 |
-3.88 |
-2.01 |
-2.4 |
| Weighted Average Shares
Out |
$33.74 M
|
$33.83 M
|
$34.94 M
|
$34.41 M
|
$33.45 M
|
$32.88 M
|
$30.27 M
|
$24.26 M
|
$13.54 M
|
$7.47 M
|
| Weighted Average Shares
Out Diluted |
$41.79 M
|
$33.83 M
|
$41.05 M
|
$35.15 M
|
$33.45 M
|
$32.95 M
|
$30.27 M
|
$24.26 M
|
$13.54 M
|
$7.47 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
